Document is current
Any future updates will be listed below
-
Authors
Chowell, Diego
Yoo, Seong-Keun https://orcid.org/0000-0002-8749-7050
Valero, Cristina https://orcid.org/0000-0003-3397-2888
Pastore, Alessandro https://orcid.org/0000-0002-3621-4807
Krishna, Chirag
Lee, Mark
Hoen, Douglas
Shi, Hongyu
Kelly, Daniel W.
Patel, Neal https://orcid.org/0000-0002-4352-4723
Makarov, Vladimir
Ma, Xiaoxiao
Vuong, Lynda
Sabio, Erich Y.
Weiss, Kate
Kuo, Fengshen https://orcid.org/0000-0003-1797-2896
Lenz, Tobias L. https://orcid.org/0000-0002-7203-0044
Samstein, Robert M.
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Adusumilli, Prasad S. https://orcid.org/0000-0002-1699-2046
Balachandran, Vinod P. https://orcid.org/0000-0002-2956-223X
Plitas, George
Ari Hakimi, A.
Abdel-Wahab, Omar https://orcid.org/0000-0002-3907-6171
Shoushtari, Alexander N.
Postow, Michael A.
Motzer, Robert J.
Ladanyi, Marc
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Gönen, Mithat
Morris, Luc G. T. https://orcid.org/0000-0002-4417-2280
Weinhold, Nils https://orcid.org/0000-0003-3290-6192
Chan, Timothy A. https://orcid.org/0000-0002-9265-0283
- License Information
-
More Information
Article History
Received: 3 December 2020
Accepted: 23 August 2021
First Online: 1 November 2021
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C., L.G.T.M. and D.C. hold ownership of intellectual property on using tumor mutational burden to predict immunotherapy response, with a pending patent, which has been licensed to PGDx. M.A.P. reports consulting fees from Bristol Myers Squibb, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro and Eisai; honoraria from Bristol Myers Squibb and Merck; and institutional support from RGenix, Infinity, Bristol Myers Squibb, Merck, Array BioPharma, Novartis and AstraZeneca. M.L. has received advisory board compensation from Merck and Bristol Myers Squibb. The remaining authors declare no competing interests.
